VEGFA and Abnormal retinal morphology: Furthermore, bevacizumab (Avastin; Roche, Basel, Switzerland) also is used off-label for treating retinal diseases, including the orphan indication of uveitic ME (UME).3, –5 However, despite the visual benefits anti-VEGF treatments have achieved, they fail to resolve ME in >20% of patients with DME6 and in >40% of patients with RVO and uveitis/UME,7,8 suggesting that there also are important alternative mediators of retinal barrier dysfunction.